-date, as well as revise the ability to pay debt and total exposure of each client on a regular basis. The securities company must retain the related documentary evidence as prescribe in the first
invests mainly in equities, the risk spectrum should point toward Equity Fund (level 6). In addition, if the fund adjusts the investment proportion significantly, the CIS Operator should revise the risk
point toward Equity Fund (level 6). In addition, if the fund adjusts the investment proportion significantly, the CIS Operator should revise the risk level of the fund Investors who seek to diversify his
significantly, the CIS Operator should revise the risk level of the CIS without delay to reflect the actual investment. Investors who seek to diversify his/her investment by investing in a wide range of asset
U City Public Company Limited (Registration No. 0107537000459) 21 TST Tower Soi Choei Phuang, Viphavadi-Rangsit Road, Chomphon, Chatuchak, Bangkok 10900, Thailand T: + 662 273 8838 F: + 662 273 8858 www.ucity.co.th Ref. No. U.SET 019/2017 October 30, 2017 Subject: Entire business transfer of Unicorn Enterprise Company Limited, capital increase, issuance of the U-W3 Warrants and U-W4 Warrants, issuance and offering of the newly issued preferred shares to be issued and offered to the existing shar...
Microsoft Word - 00. Project Unicorn - ELCLID of U - Revised Offering Price EN v2 (05122017) - clean.docx 1 (-Translation-) Ref. No. U.SET 024/2560 December 6, 2017 Subject: Notification on the Change of Details Concerning the Entire Business Transfer of Unicorn Enterprise Company Limited, Capital Increase, Issuance and Allocation of U-W3 and U-W4 Warrants, and Issuance and Offering of Newly Issued Preferred Shares to Specific Investors To: The President Stock Exchange of Thailand Enclosures: 1....
exceeding 10 percent of such fair price and the price must be in the best interest of the Company and the shareholders, Whereby empowered to determine and/or revise the sale and allocation of newly issued
exceeding 10 percent of such fair price and the price must be in the best interest of the Company and the shareholders, Whereby empowered to determine and/or revise the sale and allocation of newly issued
the Company does not undertake any duty or obligation to supplement, amend, update or revise any such statements. The Company does not make any representation, warranty or prediction that the results
the Company does not undertake any duty or obligation to supplement, amend, update or revise any such statements. The Company does not make any representation, warranty or prediction that the results